Similarly, Berrien-Elliot et al., have shown that gene-editing using CRISPR/CAS9 to delete NKG2A from human NK cells was able to increase NK cell ability to control HLA-E+ K562 leukemia when compared to control NK cells demonstrating a substantial inhibitory function for NKG2A (129). This evidence concerns the gene KLRC1 and leukemia.